Comparison 3. Nitrates vs Alpha‐1 Antagonist.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total Serious Adverse Events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 All cause mortality	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.1 Nitroglycerine vs Urapidil	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Non‐fatal cardiovascular events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Acute Myocardial Infarction	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.09, 3.17]
4.1 Nitroglycerin vs. Urapidil	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	0.55 [0.09, 3.17]
5 Respiratory insufficiency requiring mechanical ventilation	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	4.12 [0.20, 84.24]
5.1 Nitroglycerine vs. urapidil	1	133	Risk Ratio (M‐H, Fixed, 95% CI)	4.12 [0.20, 84.24]
6 Withdrawals due to adverse events	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	3.38 [0.17, 68.84]
6.1 Nitroglycerine vs Urapidil	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	3.38 [0.17, 68.84]
7 Mean change in systolic blood pressure during treatment	2	193	Mean Difference (IV, Fixed, 95% CI)	‐3.94 [‐9.31, 1.43]
7.1 Nitroprusside vs Urapidil	1	81	Mean Difference (IV, Fixed, 95% CI)	‐20.80 [‐28.27, ‐13.33]
7.2 Nitroglycerine vs Urapidil	1	112	Mean Difference (IV, Fixed, 95% CI)	14.0 [6.29, 21.71]
8 Mean change in diastolic blood pressure during treatment	2	193	Mean Difference (IV, Fixed, 95% CI)	0.76 [‐2.70, 4.23]
8.1 Nitroprusside vs Urapidil	1	81	Mean Difference (IV, Fixed, 95% CI)	‐10.80 [‐16.27, ‐5.33]
8.2 Nitroglycerine vs Urapidil	1	112	Mean Difference (IV, Fixed, 95% CI)	8.5 [4.03, 12.97]
9 Mean change in heart rate during treatment	2	193	Mean Difference (IV, Fixed, 95% CI)	‐1.10 [‐5.93, 3.72]
9.1 Nitroprusside vs Urapidil	1	81	Mean Difference (IV, Fixed, 95% CI)	1.0 [‐6.64, 8.64]
9.2 Nitroglycerine vs Urapidil	1	112	Mean Difference (IV, Fixed, 95% CI)	‐2.5 [‐8.73, 3.73]